Carlo Torti

Summary

Country: Italy

Publications

  1. ncbi request reprint Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
  2. ncbi request reprint Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Curr HIV Res 6:43-8. 2008
  3. ncbi request reprint Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART)
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Viral Immunol 17:279-86. 2004
  4. ncbi request reprint Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    J Antimicrob Chemother 56:190-5. 2005
  5. ncbi request reprint A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regi
    Carlo Torti
    Institute for Infectious and Tropical Diseases, Brescia, Italy
    Clin Infect Dis 40:1828-36. 2005
  6. ncbi request reprint Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
  7. ncbi request reprint Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:139-42. 2004
  8. ncbi request reprint Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients
    C Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 18:629-34. 2004
  9. doi request reprint Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications
    C Torti
    Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    Epidemiol Infect 138:1298-307. 2010
  10. doi request reprint Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts
    C Torti
    School of Medicine, Institute of Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 1, 25123, Brescia, Italy
    Infection 37:244-9. 2009

Detail Information

Publications89

  1. ncbi request reprint Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
    ..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure...
  2. ncbi request reprint Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Curr HIV Res 6:43-8. 2008
    ..Further studies are needed to compare pVL decay between antiretroviral regimens and assess whether proviral HIV-DNA load is a surrogate marker of treatment effectiveness...
  3. ncbi request reprint Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART)
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Viral Immunol 17:279-86. 2004
    ....
  4. ncbi request reprint Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    J Antimicrob Chemother 56:190-5. 2005
    ....
  5. ncbi request reprint A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regi
    Carlo Torti
    Institute for Infectious and Tropical Diseases, Brescia, Italy
    Clin Infect Dis 40:1828-36. 2005
    ....
  6. ncbi request reprint Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously...
  7. ncbi request reprint Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:139-42. 2004
  8. ncbi request reprint Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients
    C Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 18:629-34. 2004
    ..In conclusion, pharmacokinetic variability and low LPV concentrations have been found, supporting the use of therapeutic drug monitoring in those starting this drug...
  9. doi request reprint Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications
    C Torti
    Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    Epidemiol Infect 138:1298-307. 2010
    ..The evidence of inter-subtype recombinants points to significant genetic assortment. Overall our results support phylogenetic analysis as a tool for epidemiological investigation in order to guide targeted prevention strategies...
  10. doi request reprint Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts
    C Torti
    School of Medicine, Institute of Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 1, 25123, Brescia, Italy
    Infection 37:244-9. 2009
    ..Although the mechanism of atazanavir (ATV)-related hyperbilirubinemia is well identified, its prevalence, risk factors, and association with transaminase flares have rarely been assessed in a large population from the "real life" setting...
  11. pmc Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    BMC Infect Dis 5:58. 2005
    ....
  12. ncbi request reprint Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 10:505-13. 2005
    ....
  13. ncbi request reprint Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients
    Carlo Torti
    School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drug Saf 30:1161-9. 2007
    ..Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV)...
  14. ncbi request reprint CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
    Carlo Torti
    Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    J Antimicrob Chemother 59:1141-7. 2007
    ..We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination...
  15. ncbi request reprint Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    Int J Antimicrob Agents 29:185-90. 2007
    ..The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk...
  16. pmc Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report
    Giuseppe Lapadula
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Med Case Reports 1:19. 2007
    ..Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage...
  17. ncbi request reprint First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006)
    G Carosi
    Clinica di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, P le Spedali Civili, 1, 25123, Brescia, Italy
    Infection 35:134-42. 2007
    ..A rational switch strategy should consider both metabolic and anthropometric disturbances and effectiveness of antiretroviral regimens...
  18. ncbi request reprint Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Med Virol 74:29-33. 2004
    ....
  19. ncbi request reprint Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    J Acquir Immune Defic Syndr 41:180-5. 2006
    ..The independent role of hepatitis C virus (HCV) genotype 3 in liver transaminase elevation following highly active antiretroviral regimens is still controversial...
  20. ncbi request reprint Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals
    C Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, 25123 Brescia, Italy
    Clin Microbiol Infect 10:826-30. 2004
    ..These findings support the use of resistance testing in patients naïve for anti-retroviral therapy, and suggest that the possible impact of newly recognised treatment-related mutations on clinical outcome requires further investigation...
  21. ncbi request reprint Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
    ..Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation...
  22. doi request reprint Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection
    Monia Mendeni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Clin Infect Dis 52:1164-73. 2011
    ..There is lack of data on the incidence of liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF...
  23. ncbi request reprint Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008
    ..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations...
  24. ncbi request reprint Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy
    Giuseppe Lapadula
    Istituto per le Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    Antivir Ther 11:521-7. 2006
    ..The independent role of HCV genotype 3 (HCV-3) in dyslipidaemia following highly active antiretroviral therapy (HAART) is still unexplored...
  25. ncbi request reprint Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome
    Massimo Puoti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, Italy
    J Acquir Immune Defic Syndr 32:259-67. 2003
    ..To assess incidence, risk factors, histology, and outcome of severe hepatotoxicity (SH) during antiretroviral treatment (ART)...
  26. ncbi request reprint Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 21:92-9. 2007
    ..4; 95% CI 0.2-0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1-5.3; p = 0.032)...
  27. ncbi request reprint Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy
    Eugenia Quiros-Roldan
    Infectious Diseases Clinic, University of Brescia, Italy
    J Clin Lab Anal 16:76-8. 2002
    ..A slow decline in the detectability of mutations encoding NNRTI resistance was found...
  28. ncbi request reprint Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3
    Giuseppe Lapadula
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    Antivir Ther 12:941-7. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events (ADE) or death among patients who started HAART with CD4+ T-cell counts > or =200 cells/mm3 have rarely been assessed simultaneously...
  29. ncbi request reprint Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Med Sci Monit 9:CS16-9. 2003
    ..Resistance testing on the proviral genome has been suggested in order to detect the presence of archived resistance mutations and to guide drug prescription...
  30. doi request reprint Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis
    Giuseppe Lapadula
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Med Virol 80:747-53. 2008
    ..38; 95% CI:0.17-0.86; P = 0.020). Prevalence of primary resistance mutations suggests that genotypic resistance testing should be performed before starting treatment in naïve patients in Italy, particularly when NNRTI are prescribed...
  31. ncbi request reprint Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study
    Andrea Patroni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 3:451-61. 2002
    ..Lipid disturbances have also been associated with hepatitis C virus (HCV) chronic infection in HIV-uninfected participants. HAART-induced lipid abnormalities may then have peculiar features in HIV-HCV co-infected individuals...
  32. ncbi request reprint Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART
    Maria Cristina Uccelli
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Ann Nutr Metab 50:247-52. 2006
    ..Homocysteinemia (Hcy) increase and risk factors in HIV-positive patients are not clear yet...
  33. ncbi request reprint Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    J Infect Dis 188:194-201. 2003
    ..52-5.52; P=.001; RetroGram: OR, 2.34; 95% CI, 1.21-4.55; P=.012), whereas, in contrast to real or virtual phenotype, interpretations according to biological cut-offs were not (OR, 1.91; 95% CI, 0.77-4.76; P=.162)...
  34. doi request reprint Screening and Management of HIV-2-Infected Individuals in Northern Italy
    Silvia Costarelli
    Institute of Infectious and Tropical Diseases, University of Brescia, Brecia, Italy
    AIDS Patient Care STDS 22:489-94. 2008
    ..Accurate screening programs and integration of virological tools must be implemented urgently, given the high prevalence of HIV-2, particularly in immigrant patients...
  35. doi request reprint Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
    Antonella Castagna
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 15:165-75. 2010
    ..The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined...
  36. doi request reprint A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz
    Laura Albini
    Department of Materno Infantile e Tecnologie Biomediche, Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Acquir Immune Defic Syndr 59:18-30. 2012
    ..There is lack of data on GFR estimated by these methods in patients on highly active antiretroviral therapy...
  37. ncbi request reprint SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression
    Eugenia Quiros-Roldan
    Department of Infectious and Tropical Diseases, Spedali Civili of Brescia, 25123, Italy
    AIDS Res Hum Retroviruses 19:1079-82. 2003
    ..At multivariate analysis, SENV infection did not appear to have any negative impact on survival, while a possible protective effect needs further investigation...
  38. ncbi request reprint Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target?
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Intervirology 47:350-4. 2004
    ....
  39. ncbi request reprint Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    Health Policy 65:261-7. 2003
    ..To assess the impact of highly active antiretroviral therapy (HAART) on health resource utilisation (HRU) and to estimate associated direct costs in a population based setting...
  40. pmc Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
    Emanuele Focà
    Infectious Diseases Department, University of Brescia, Brescia, Italy
    BMC Infect Dis 12:38. 2012
    ..Lastly, the effect of tenofovir on 1,25-(OH)₂ vitamin D is uncertain...
  41. doi request reprint Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use
    Emanuele Focà
    Department for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drugs 72:1161-73. 2012
    ..Moreover, therapeutic drug monitoring could be useful in specific circumstances (such as in patients with liver impairment or in case of potential drug-drug interactions)...
  42. ncbi request reprint Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop
    Giampiero Carosi
    Department of Infectious Disease, University of Brescia, Brescia, Italy
    AIDS Rev 7:161-7. 2005
    ....
  43. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  44. ncbi request reprint Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy
    Emanuele Focà
    Infectious Diseases Department, University of Brescia, Brescia, Italy
    New Microbiol 35:227-31. 2012
    ..At the same time, HAART proved effective in reducing HCMV DNAemia without the need for a specific therapy...
  45. pmc Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy)
    Ilaria Izzo
    Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    BMC Public Health 11:124. 2011
    ..Therefore, we examined pregnant women by regional provenance and measured variables that could be associated with detectable HIV RNA at delivery...
  46. ncbi request reprint A king in the CASTLE? Optimum initial HIV protease inhibitor
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, I 25123 Brescia, Italy
    Lancet 372:604-6. 2008
  47. ncbi request reprint Natural history of chronic hepatitis B in co-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili, Universita di Brescia, P zzle Spedali Civili 1, I 25123 Brescia, Italy
    J Hepatol 44:S65-70. 2006
    ....
  48. ncbi request reprint Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex Study
    C Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Med 4:263-70. 2003
    ..To assess prevalence and predictive factors of viro-immunological discordant trends in a cohort of heavily pretreated patients...
  49. pmc Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
    Davide Motta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Res Ther 9:18. 2012
    ..abstract:..
  50. pmc Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance
    Manuela Fogli
    Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, Spedali Civili Square, 25123 Brescia, Italy
    Clin Dev Immunol 2012:829584. 2012
    ..These results provide new insights on B cell in HIV-1 infection and show that development of B cell abnormalities precedes CD4⁺ T cell decline...
  51. doi request reprint High prevalence of radiological vertebral fractures in HIV-infected males
    Carlo Torti
    Institute of Infectious and Tropical Diseases, School of Medicine, University of Brescia, P le Spedali Civili, 1, 25123 Brescia, Italy
    Endocrine 41:512-7. 2012
    ..Furthermore, proactive diagnosis of vertebral fragility fractures is particularly relevant in patients who are overweight or suffer from diabetes...
  52. ncbi request reprint For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features
    Manuela Fogli
    Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Piazzale Spedali Civili, Brescia, Italy
    New Microbiol 37:75-80. 2014
    ..Results obtained suggest that a combination of these parameters could be an adequate surrogate marker of immunological competence. This will be helpful in deciding when to start HAART. ..
  53. pmc Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients
    Eugenia Quiros-Roldan
    Laboratory of Biotechnology, Diagnostics Department, Spedali Civili of Brescia, Brescia, Italy
    J Transl Med 10:94. 2012
    ....
  54. ncbi request reprint [New strategies and new drugs in the salvage therapy for HIV infection]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Med Clin (Barc) 118:222-4. 2002
  55. ncbi request reprint Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch
    L R Tomasoni
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 4:311-23. 2003
    ..To assess predictive factors of long-term immune restoration in patients who started protease inhibitor (PI)-based HAART and experienced virological rebound after initial complete success...
  56. ncbi request reprint HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment
    E Quiros-Roldan
    Clinica de Malattie Infettive e Tropicali, , Italy
    Microbios 106:137-45. 2001
    ..85%) than in other studies, which ranged from 2 to 19%. The M184V mut seemed to confer some viro-immunological benefit when associated with the Q151M mutation, compared with the latter alone...
  57. ncbi request reprint "Solving the puzzle" of current HAART: what key strategic trials are needed?
    G Carosi
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Brescia, Italy
    New Microbiol 27:127-30. 2004
    ..As a consequence, new more effective and tolerable antiretroviral agents and regimens are needed, as well as new strategies for HIVdisease management. Strategically driven clinical researches are needed to address these issues...
  58. ncbi request reprint [A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009]
    Alessandra Calabresi
    Clinica di Malattie Infettive e Tropicali, Universita degli Studi di Brescia
    Epidemiol Prev 37:153-60. 2013
    ..to complete the database of all patients infected by the human immunodeficiency virus (HIV) who lives in the area belonging to the Local Health Unit (ASL) of Brescia, Northern Italy,with all the cancers diagnosed in the period 1999-2009...
  59. ncbi request reprint Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy
    E Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Clin Lab Anal 15:43-6. 2001
    ..Twelve of our patients (12.9%) had no mutation encoding drug resistance and were completely sensitive to all RT and protease inhibitors. Therefore, not all virological failures are caused by HIV-1 genomic resistance...
  60. ncbi request reprint HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens
    E Quiros-Roldan
    Institute of Infectious and Tropical Diseases, Spedali Civili of Brescia, University of Brescia, Brescia, Italy
    J Clin Lab Anal 19:26-9. 2005
    ..The use of NFV as a first-line PI, as an application of drug sequencing strategies, may help preserve future PI options...
  61. ncbi request reprint Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection
    E Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    Eur J Clin Microbiol Infect Dis 24:436-7. 2005
  62. ncbi request reprint [The novel non-A, non-E hepatitis viruses and their pathogenic effect]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, Spedali Civili, Brescia, Italy
    Med Clin (Barc) 122:552-4. 2004
    ..Only a careful evaluation of the data and the scientific concordance of all the evidence will resolve the question of whether they are only commensal viruses or pose a real pathogenic potential...
  63. ncbi request reprint Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules
    Daria Gotti
    Institute for Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    Curr HIV Res 9:61-9. 2011
    ....
  64. pmc Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 125123 Brescia, Italy
    BMC Med 9:138. 2011
    ..Moreover, it is important to understand whether new biomarkers or neuroimaging tools can help to identify better the most at risk population. Please see related article: http://www.biomedcentral.com/1471-2334/11/356...
  65. pmc HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
    Antonella D arminio Monforte
    Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Polo Universitario San Paolo, via A Di Rudinì 8 20142 Milano, Italy
    AIDS 22:2143-53. 2008
    ..To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency...
  66. ncbi request reprint Key questions in antiretroviral therapy: Italian Consensus Workshop (2005)
    G Carosi
    Department of Infective and Tropical Diseases, University of Brescia, Piazzale Spedali Civili I, I 25123 Brescia, Italy
    J Antimicrob Chemother 57:1055-64. 2006
    ..Main conclusions are summarized and critically discussed in this consensus statement, as well as some of the most recent data supporting these recommendations are provided...
  67. ncbi request reprint Soil transmitted helminth (STH) infections in an indigenous community in Ortigueira, Paraná, Brazil and relationship with its nutritional status
    A Beltrame
    Department of Infectious and Tropical Diseases, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    Parassitologia 44:137-9. 2002
    ..These results strongly suggested that mass treatment would be indicated in the indigenous community, possibly leading to improved nutritional status...
  68. ncbi request reprint Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy
    Maria Cristina Uccelli
    AIDS 17:141-3. 2003
  69. ncbi request reprint Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy
    Carlo Torti
    J Acquir Immune Defic Syndr 29:315-7. 2002
  70. ncbi request reprint Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound
    Lina Tomasoni
    J Infect Dis 186:445-6. 2002
  71. ncbi request reprint HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations
    Luigia Scudeller
    Institute of Infectious Diseases, University of Udine, Udine
    J Antimicrob Chemother 52:776-81. 2003
    ..The objective was to study genotypic correlates of discordant interpretations of amprenavir (APV) resistance between a rules-based algorithm and either recombinant phenotype or virtual phenotype...
  72. ncbi request reprint Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial
    Francesco Mazzotta
    Department of Infectious Diseases, S M Annunziata Hospital, ASL Firenze, Italy
    J Acquir Immune Defic Syndr 32:268-80. 2003
    ..Several factors should be considered to take better advantage of resistance testing, including treatment history, clinical status, and patients' ability to adhere to treatment...
  73. ncbi request reprint The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 11:923-9. 2006
    ..One of the more vigorous debates in the field of highly active antiretroviral therapy (HAART) is how to start it and what the optimal drug sequence is...
  74. ncbi request reprint Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study
    Nicola Gianotti
    Clinica di Malattie Infettive, Universita Vita Salute San Raffaele, Milan, Italy
    Clin Infect Dis 42:1470-80. 2006
    ..There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results...
  75. ncbi request reprint The development of artificial neural networks to predict virological response to combination HIV therapy
    Brendan Larder
    The HIV Resistance Response Database Initiative, London, UK
    Antivir Ther 12:15-24. 2007
    ..The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation of resistance from genotypic data poses a major challenge...
  76. ncbi request reprint [Usefulness of pharmacokinetics in the management of antiretroviral therapy]
    Eugenia Quiros-Roldan
    Med Clin (Barc) 124:695-6. 2005
  77. ncbi request reprint No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients
    Silvia Costarelli
    J Acquir Immune Defic Syndr 46:255-6. 2007
  78. ncbi request reprint Genotyping for guiding drug choice in human immunodeficiency virus-infected children failing multiple antiretroviral treatment regimens
    Raffaele Badolato
    Pediatr Infect Dis J 24:747-9. 2005
  79. ncbi request reprint Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 12:1175-83. 2007
    ..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...
  80. doi request reprint Response to combination antiretroviral therapy: variation by age
    Caroline A Sabin
    AIDS 22:1463-73. 2008
    ..To provide information on responses to combination antiretroviral therapy in children, adolescents and older HIV-infected persons...
  81. ncbi request reprint Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations
    Carlo Torti
    J Acquir Immune Defic Syndr 35:324-6. 2004
  82. doi request reprint Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART
    Annalisa Saracino
    Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
    J Med Virol 80:1695-706. 2008
    ..Therefore, in some cases DNA plus RNA genotyping might assist in choosing more accurately subsequent antiretroviral regimens...
  83. ncbi request reprint HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations
    Carlo Torti
    J Acquir Immune Defic Syndr 36:1104-7. 2004
  84. ncbi request reprint Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen)
    Annalisa Saracino
    Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
    J Acquir Immune Defic Syndr 37:1587-98. 2004
    ..55; P = 0.001), and adherence to expert advice (OR = 0.37; P < 0.001) predicted virologic response. The vPt is as predictive of treatment outcome as the rPT. Use of expert advice significantly improved the response to therapy...
  85. doi request reprint Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients
    Giuseppe Lapadula
    Clin Infect Dis 46:1127-9. 2008
  86. ncbi request reprint No evidence of benefical effect of GB virus type C infection on the course of HIV infection
    Eugenia Quiros-Roldan
    AIDS 16:1430-1. 2002
  87. pmc Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis
    Andrea Gori
    Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano Bicocca, Via Solferino 16 20052, Milan, Italy
    J Clin Microbiol 46:757-8. 2008
    ..This impairment is associated with alterations in gut microbiota and intestinal inflammatory parameters. These findings support the hypothesis that alterations at the gastrointestinal-tract level are a key factor in HIV pathogenesis...
  88. ncbi request reprint Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
    Giulio Perugi
    Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, Psychiatry Section, University of Pisa, Pisa, Italy
    J Clin Psychopharmacol 22:584-91. 2002
    ..What is new in the present report is the suggestion that the utility of GBP in resistant bipolar disorder resides in its effectiveness against comorbid panic disorder and alcohol abuse...
  89. ncbi request reprint Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response
    Giulio Perugi
    Institute of Behavioral Sciences G De Lisio, Carrara, Italy
    Neuropsychobiology 46:145-9. 2002
    ..Our data confirm the effectiveness and tolerability of SR-VF in mixed anxiety-depressive states. The differential response suggests a pathophysiologic and clinical distinction between GAD with comorbid MD or dysthymia...